Preclinical alzheimer's disease therapeutics

Journal of Alzheimer's Disease

Volumn 42, Issue , 2014, Pages S545-S549

  Rafii, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; preclinical Alzheimer's disease

Indexed keywords

BIOLOGICAL MARKER; CENTRAL NERVOUS SYSTEM AGENTS; NEUROLEPTIC AGENT;

ALZHEIMER DISEASE; AUTOSOMAL DOMINANT INHERITANCE; CLINICAL DEMENTIA RATING; COGNITION; COGNITIVE DEFECT; DEMENTIA; DISEASE COURSE; DRUG SCREENING; HUMAN; MEMORY; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; REVIEW; SECONDARY PREVENTION; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MODEL;

ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS;

EID: 84908213913     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141482     Document Type: Review

References (25)

1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer's disease. Lancet 377, 1019-1031.
2. Dubois B, Albert ML (2004) Amnestic MCI or prodromal Alzheimer's disease? Lancet Neurol 3, 246-248.
3. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
4. Hampel H, Lista S, Teipel SJ, Garaci F, Nisticó R, BlennowK, ZetterbergH, Bertram L, Duyckaert C, Bakardjian H, Drzezga A, Colliot O, Epelbaum S, Broich K, Lehé ricy S, Brice A, Khachaturian ZS, Aisen PS, Dubois B (201 4) Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease:Along-range point of viewbeyond 2020. Biochem Pharmacol 88, 426-449.
5. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G, Fripp J, Tochon-Danguy H, Morandeau L, O'Keefe, Price R, Raniga P, Robins P, Acosta O, Lenzo N, Szoeke C, Salvado O, Head R, Martins R, Masters CL, Ames D, Villemagne VL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 31, 1275-1283.
6. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps C H (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 28 0-292.
7. Jack CR Jr., Knopman DS,Weigand SD,Wiste HJ, Vemuri P, LoweV, Kantarci K, Gunter JL, SenjemML,Ivnik RJ, Roberts RO, RoccaWA, BoeveBF, PetersenRC(2012)Anoperational approach to National Instit ute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71, 765-775.
8. US Dept of Health and Human Services; US Food and Drug Administration; Center for Drug Evaluation and Research (2013) Guidance for industry: Alzheimer's disease: Developing drugs for the treatment of early stage disease (draft guidance). http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM338287. Pdf
9. Kozauer N, Katz R (2013) Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med 368, 1169-1171.
10. Trojanowski JQ, Vanderstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers S, Potter WZ, Weiner MW, Jack CR Jr., Jagust W, Toga AW, Lee VM-Y, Shaw LM, The Alzheimer's Diseas e Neuroimaging, Initiative (2010) Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement 6, 230-238.
11. Villemagne VL, Burnham S, Bourgeat P, Brown B, Elli s KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Australian Imaging Biomarkers, Lifestyle (AIBL) Research, Group (2013) Amyloid beta deposition, neurodegeneration, and c ognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 12, 357-367.
12. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE,McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC, Dominantly Inherited Alzheimer, Network (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367, 795-804.
13. Reiman EM,QuirozYT, Fleisher AS,Chen K,Velez-Pardo C,Jimenez-Del-Rio M,Fagan AM,Shah AR,Alvarez S,Arbelaez A,Giraldo M,Acosta-Baena N,Sperling RA,Dickerson B,Stern CE,Tirado V,Munoz C,R e iman RA,Huentelman MJ,Alexander GE,Langbaum JB,Kosik KS,Tariot PN,Lopera F 2012 Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: A case-control study Lancet Neurol 12, 1048-1056.
14. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ (1997) Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer D is Assoc Disord 11, S13-S21.
15. Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS; for the Australian Imaging, Biomarkers, and Lifestyle Flagship S tudy of Ageing; the Alzheimer's Disease Neuroimaging Initiative; and the Alzheimer's Disease Cooperative Study (2014) The Preclinical Alzheimer Cognitive Composite: Measuring amyloid-related decline. JAMA Neurol, doi: 10.1001/jamaneurol.2014.803 .
16. Langbaum JB, Hendrix SB, Ayutyanont N, Chen K, Fleisher AS, Shah RC, Barnes LL, Bennett DA, Tariot PN, Reiman EM (2014) An empirically derived composite cognitive test score with improve d power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement, doi: 10.1016/j.jalz.2014.02.002.
17. Selkoe DJ (2011) Alzheimer's disease. Cold Spring Harb Perspect Biol 3, pii: a004457.
18. Selkoe DJ (2008) Biochemistry and molecular biology of amyloid beta-protein and the mechanism of Alzheimer's disease. Handb Clin Neurol 89, 245-260.
19. Viswanathan A, Greenberg SM (2011) Cerebral amyloid angiopathy in the elderly. Ann Neurol 70, 871-880.
20. Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8, 663-672.
21. Iqbal K, Alonso AC, Gong CX, Khatoon S, Pei JJ, Wang JZ, Grundke-Iqbal I (1998) Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. J Neural Transm 53, 169-180.
22. Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, Aisen P (2014) The A4 study: Stopping AD before symptoms begin? Sci Transl Med 19, 228.
23. Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, Quiroz YT, Kosik KS, Lopera F , Tariot PN (2011) Alzheimer's Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 3, 321-329.
24. Mills SM1, Mallmann J, Santacruz AM, Fuqu a A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, Farlow M, Fox N, Ghetti B, Goate AM, Heinrichs D, Hornbeck R, Jack C, Jucker M, Klunk WE, Marcus DS, Martins RN, Masters CM, Mayeux R, McDade E, Morris JC, Oliver A, Ringman JM, Rossor MN, Salloway S, Schofield PR, Snider J, Snyder P, Sperling RA, Stewart C, Thomas RG, Xiong C, Bateman RJ (2013) Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial. Rev Neurol (Paris) 169, 737-743.
25. Ness S, Rafii M, Aisen P, Krams M, Silverman W, Manji H (2012) Down's syndrome and Alzheimer's disease: Towards secondary prevention. Nat Rev Drug Discov 11, 655-656.